Trials / Completed
CompletedNCT01138657
Efficacy and Safety of Adalimumab in Patients With Active Uveitis
A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis - Including a Sub-study in Japanese Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 239 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A study comparing the safety and efficacy of adalimumab compared with placebo in patients with active uveitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Adalimumab | Administered subcutaneously as an 80 mg loading dose (2 syringes) at Baseline followed by a 40 mg dose eow starting at Week 1. |
| DRUG | Prednisone | Administered orally, 60 mg/day at study entry followed by a protocol-defined mandatory taper schedule in which all participants continuing in the study were to discontinue prednisone no later than Week 15. |
| DRUG | Placebo | Administered by subcutaneous injection |
Timeline
- Start date
- 2010-08-01
- Primary completion
- 2014-07-01
- Completion
- 2014-08-01
- First posted
- 2010-06-07
- Last updated
- 2021-07-07
- Results posted
- 2016-08-22
Source: ClinicalTrials.gov record NCT01138657. Inclusion in this directory is not an endorsement.